What Is BI 3034701? The New GLP-1, GIP and NPY2 Triple Agonist

Multi-receptor metabolic research is moving into increasingly sophisticated territory.

Researchers have already developed compounds combining GLP-1 with GIP, glucagon and amylin-related pathways.

Now another signalling system is entering the picture:

Neuropeptide Y.

BI 3034701 is an investigational compound developed by Boehringer Ingelheim that combines activity at three receptors:

GLP-1

GIP

and

NPY2.

The compound entered Phase 2 clinical development in 2026, making it one of the newest multi-receptor programmes to reach this stage of human research.

What Is BI 3034701?

BI 3034701 is an investigational triple receptor agonist being studied in people with obesity or overweight.

It has been designed to activate:

GLP-1 receptors

• ●

GIP receptors

• ●

neuropeptide Y2 receptors

The first two pathways will already be familiar to anyone following modern metabolic research.

The third is considerably less familiar.

And that’s what makes BI 3034701 particularly interesting.

What Is Neuropeptide Y?

Neuropeptide Y — usually abbreviated to NPY — is a peptide involved in signalling within the nervous system.

It belongs to a family of biologically related peptides involved in processes including appetite and energy regulation.

Rather than having one receptor, the neuropeptide Y system contains several receptor subtypes.

These include:

Y1

Y2

Y4

and Y5 receptors.

Different receptors can produce different biological responses.

BI 3034701 specifically targets the Y2 receptor, often written as NPY2R or Y2R.

What Is the NPY2 Receptor?

The Y2 receptor participates in signalling involved in the regulation of food intake.

One naturally occurring peptide that strongly interacts with Y2 receptors is peptide YY, or PYY.

PYY is produced primarily within the gastrointestinal tract and released following food intake.

A shortened circulating form called PYY3-36 can activate Y2 receptors involved in appetite-related signalling.

This creates an interesting connection between:

the intestine

and

the brain.

Researchers sometimes describe these interconnected systems collectively as part of the gut–brain axis.

What Is PYY?

Peptide YY is a naturally occurring peptide hormone released from specialised endocrine cells within the intestine.

Its circulating concentration generally increases following food intake.

Researchers have investigated PYY because it participates in signalling associated with satiety and regulation of food consumption.

PYY therefore belongs to a much broader family of metabolic signals that includes GLP-1, GIP, glucagon and other gastrointestinal hormones.

But it works through different receptors.

That makes the PYY–Y2 pathway an interesting potential complement to established incretin biology.

Why Combine NPY2 With GLP-1 and GIP?

This is the central scientific idea behind BI 3034701.

GLP-1 and GIP already provide two metabolic signalling pathways.

Adding NPY2 potentially introduces another mechanism related to the central regulation of hunger, appetite and food intake.

Rather than simply increasing activity at established incretin receptors, researchers can investigate whether combining peripheral metabolic signalling with another gut–brain signalling system produces a different biological response.

Boehringer Ingelheim describes the approach as combining GLP-1/GIP-mediated metabolic regulation with NPY2-driven central control of food intake.

Is BI 3034701 the Same as Retatrutide?

No.

Although both are described as triple agonists, their third receptor is completely different.

Retatrutide targets:

GLP-1 + GIP + glucagon

BI 3034701 targets:

GLP-1 + GIP + NPY2

That single difference substantially changes the pharmacological hypothesis.

Retatrutide incorporates the glucagon receptor, which has important roles in hepatic and energy metabolism.

BI 3034701 instead introduces the neuropeptide Y2 receptor and therefore a different appetite-related signalling mechanism.

This demonstrates why the term “triple agonist” doesn’t describe one single class of compound.

The actual receptors matter.

Why NPY2 Is Particularly Interesting

Appetite isn’t controlled by one hormone.

The brain receives numerous signals carrying information about:

• nutrient intake
• gastrointestinal activity
• stored energy
• blood glucose
• hormonal state
• environmental cues

These signals are integrated within complex neural circuits.

The NPY system is one part of that network.

Targeting Y2 signalling alongside established incretin pathways therefore represents an attempt to influence metabolic regulation through multiple complementary biological systems.

BI 3034701 Entered Phase 2 in 2026

Boehringer Ingelheim announced in July 2026 that BI 3034701 had entered Phase 2 clinical development.

The study is investigating the compound in people living with obesity or overweight.

Phase 2 research is an important development stage.

Researchers begin investigating questions including:

Does the biological mechanism produce the expected effects in a larger human population?

How does response vary across different exposures?

What adverse effects occur?

What should be studied in subsequent trials?

At this stage, BI 3034701 remains experimental.

Its ultimate efficacy and safety profile cannot yet be established from the available evidence.

Why Phase 2 Matters

Many experimental molecules show interesting laboratory or early clinical results.

Far fewer successfully progress through increasingly large controlled trials.

Phase 2 therefore represents an important transition.

The research moves beyond establishing whether a compound can simply be administered to humans.

Investigators begin gathering substantially more information about its potential clinical effects.

The results from BI 3034701’s Phase 2 programme should consequently tell researchers much more about whether adding NPY2 activity provides meaningful differentiation.

The Rise of Polyhormonal Research

BI 3034701 also demonstrates a wider change occurring within metabolic science.

Researchers increasingly recognise that human metabolism is controlled by networks of hormones rather than isolated pathways.

Eating can trigger sequential release of several gut-derived signals.

These include:

cholecystokinin

GLP-1

PYY

and

GIP.

These signals then communicate with the nervous system and other organs.

Modern pharmacology is increasingly attempting to reproduce or modify aspects of these naturally occurring multi-hormone responses.

Beyond GLP-1

GLP-1 has been enormously important for metabolic research.

But the success of one pathway naturally raises another question:

What happens when additional biological signals are incorporated?

Researchers are now investigating combinations involving:

• GIP
• glucagon
• amylin
• NPY2
• muscle-related signalling
• liver-directed mechanisms
• entirely different metabolic hormones

BI 3034701 represents one branch of this diversification.

Could Appetite Research Become More Brain-Focused?

Potentially.

Many metabolic hormones ultimately communicate with the central nervous system.

The next generation of research may therefore increasingly examine precisely which neural circuits receive those signals.

Instead of treating appetite as a single biological switch, researchers can investigate the individual pathways controlling:

hunger

satiety

meal termination

food motivation

and other aspects of feeding behaviour.

NPY receptor research fits directly into this broader scientific movement.

Why BI 3034701 Is Worth Watching

BI 3034701 is still at a relatively early clinical stage compared with compounds already undergoing large Phase 3 programmes.

That uncertainty is important.

There is currently no basis for assuming that adding NPY2 agonism will necessarily make the compound more effective or better tolerated than existing approaches.

That’s exactly what clinical research needs to establish.

But scientifically, BI 3034701 introduces a particularly interesting idea:

Combine established incretin signalling with a different appetite-regulating peptide pathway within one molecule.

If the Phase 2 programme produces useful results, the NPY2 receptor could become a much more prominent target within next-generation metabolic research.

Whether that happens will depend on the evidence.

For now, BI 3034701 provides an excellent example of just how rapidly the field is moving beyond conventional GLP-1 pharmacology.

Research Notice: BI 3034701 is an investigational compound currently undergoing clinical research. It is not an approved medicine. This article is provided for scientific and educational purposes only and does not provide medical advice, treatment recommendations or dosing guidance.